Pharmacologic treatment of generalized anxiety disorder (Q32064646)

6 July 2017

1 reference

title

Pharmacologic treatment of generalized anxiety disorder (English)

1 reference

generalized anxiety disorder

6 July 2017

main subject

1 reference

Brawman-Mintzer O

1

1 reference

6 July 2017

publication date

1 March 2001

1 reference

Psychiatric Clinics of North America

6 July 2017

published in

1 reference

6 July 2017

volume

24

1 reference

6 July 2017

issue

1

1 reference

6 July 2017

page(s)

119-137

1 reference

A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting

6 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Psychiatric comorbidity in patients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Assessment of the Efficacy of Buspirone in Patients Affected by Generalized Anxiety Disorder, Shifting to Buspirone From Prior Treatment with Lorazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Recent clinical trials of hydroxyzine in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Comparison of withdrawal of buspirone and diazepam: a placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

The comparative efficacy of buspirone and diazepam in the treatment of anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Mirtazapine in major depression with comorbid generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Anxious and nonanxious depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Alcohol and depression in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Recent developments in the psychopharmacology of anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Long-term follow-up of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Evaluation of the ratings comprising the associated symptom criterion of DSM-III-R generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

The impact of comorbid mood and personality disorders in the cognitive-behavioral treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Diagnosis and outcome: depression and anxiety in a general population

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

The Prognosis of Anxiety Neurosis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Buspirone: anxiolytic?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Gabapentin as a potential treatment for anxiety disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Effect of personality disorders on the treatment outcome of axis I conditions: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Relapse after Short-Term Drug Therapy in Neurotic Outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

A controlled clinical trial of alprazolam for the treatment of anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

The Clinical Course and Long-Term Management of Generalized Anxiety Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Long-term Treatment of Anxiety and Risk of Withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Alprazolam and oxazepam in the treatment of anxious out-patients with depressive symptoms: a double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Paroxetine efficacy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Clinical aspects of chronic use of alprazolam and lorazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Effects of SSRIs on sexual function: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

The impact of clinically diagnosed personality disorders on acute and one-year outcomes of electroconvulsive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Cost of anxiety disorders: impact of comorbidity.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

A 5-Year Follow-up Study of Generalized Anxiety Disorder and Panic Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

Phenomenology and course of generalised anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970209-4

7 January 2021

10.1016/S0193-953X(05)70209-4

Identifiers

DOI

1 reference

6 July 2017

1 reference